Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (1137)	9/18/2003 7:18:20 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

I've got a ton. But I'm really, really busy. Back at you soon. Simple starters..... (1) Is SLV320 from Cadus? (2) If so, what is guidance for royalty from OSI? (3) OSI has gone "total oncology", and is looking to spin out or outlicense the GPCR/adenosine receptor stuff. Has Cadus considered, in return for royalties, reacquiring the program as part of a larger biotech merger? I told Ms. Paige that I prefer one way communications, with no feedback. She may just be doing too good of a job at what I asked for.